Can a drug restore hand blood flow in scleroderma?
NCT ID NCT01395732
First seen Jun 07, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This study tested the drug bosentan in 18 adults with systemic sclerosis (scleroderma) who had poor blood flow in their hands and a history of digital ulcers. The goal was to see if bosentan could improve hand blood flow, measured by laser imaging, and to understand how blood flow relates to ulcer severity. The trial is complete, but results are not yet widely reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Erasmus MC
Rotterdam, 3015CE, Netherlands
-
Isala Klinieken
Zwolle, 8011JW, Netherlands
-
LUMC
Leiden, 2333ZA, Netherlands
-
MCL
Leeuwarden, 8934AD, Netherlands
-
MUMC
Maastricht, 6229HX, Netherlands
-
Maasstad Ziekenhuis
Rotterdam, 3078HT, Netherlands
-
Sint Franciscus Gasthuis
Rotterdam, 3045PM, Netherlands
-
UMC Groningen
Groningen, 9700RB, Netherlands
-
UMC St Radboud
Nijmegen, 6525GA, Netherlands
-
VUmc
Amsterdam, 10811HV, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bosentan
What this could lead to
If successful, this could show that bosentan improves hand blood flow and reduces digital ulcers in scleroderma patients.
What could go wrong
This is a small, early-phase study with only 18 participants, so results may not apply widely. Bosentan also has known side effects like liver problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.